BEARINGPOINT
22.4.2021 09:57:05 CEST | Business Wire | Press release
Climate change is increasing pressure on companies to take immediate actions to measure, manage, and report greenhouse gas emissions from their operations and value chains. In its recent client story, management and technology consultancy BearingPoint shows how it supported Wipak, a global supplier of packaging solutions and services, in taking a significant step on its journey to reducing its carbon footprint to zero by 2025 by accurately calculating its carbon emissions and gaining transparency across the entire product life-cycle process.
BearingPoint leveraged its Emissions Calculator solution and used a cradle-to-gate approach during a series of workshops to identify Wipak’s key impact areas and aligned them with data requirements. The team then analyzed the processes and data availability for material acquisition, freight transportation, manufacturing sites, warehouses, and support processes related to sales offices and business travel. All data was centralized in a collection plan to feed BearingPoint’s standard data templates, followed by integrating it into the software solution. This resulted in a corporate carbon footprint (CCF), including scopes 1, 2, and 3 according to the Greenhouse Gas Protocol (GHG). Wipak also added the product carbon footprint (PCF) module to support sharing carbon data with clients down to the product level. BearingPoint supported the client to select the allocation methods and relevant secondary data sources, determining every product’s climate impact, from raw material sourcing to their recycling or disposal.
Mika Niemelä, Partner at BearingPoint: “Consumer perception and corporate customers’ demands regarding sustainable packaging are driving Wipak to seek flexible and resource-efficient solutions. At the same time, Wipak needed to ensure accurate carbon footprint calculations to comply with future sustainability regulations and laws, and it now can with our Emission Calculator solution. Today, with our solution, the company is well on its way to achieving a zero-carbon footprint by 2025.”
Wipak can now accurately calculate its carbon emissions that allow for tracking its achievements toward decarbonization on a daily level. Already from the validation phase, the application assesses and summarizes more than 1,400 purchased goods, 3,500 semi-finished products, and 4,700 finished products daily, based on a big data approach.
BearingPoint’s Emissions Calculator also enables the company to make data-driven business decisions toward reducing its carbon footprint to zero by 2025, based on all information centralized in one place and analytic tool-derived insights. The solution offers a comprehensive picture of which region, business line, or product is causing the highest emissions. Wipak also benefits from continuous updates from leading standards such as GHG protocol, ISO 14064, ISO 14067, or GLEC. This ensures that the company is better prepared to meet internal audit requirements, as well as to comply with future sustainability regulations and laws.
Dorit Nelke-Bruhn, Manager Sustainability Processes and Patents, Wipak Group: “To support us on our journey to become the most sustainable flexible packaging company, we were searching for a professional and trusted carbon accounting software to calculate corporate and product carbon footprints. BearingPoint’s Emissions Calculator fulfills our needs. It supports us to assess GHG emissions of raw materials, our production facilities, freight transportation, and support processes such as business travel and sales offices and to identify emission reduction potentials.”
About Wipak Group
Wipak is part of the family owned Wihuri Group, a diverse Finnish conglomerate that can trace its origins back over 100 years. Today the Wihuri group employs 5,000 people with operations in 30 countries.
Wihuri´s Packaging business is one of the world's leading producers of packaging materials and solutions for the Food and Medical supply industries in Europe and North America. Wihuri’s Packaging Division consists of two international brands: WIPAK in Europe and Asia and WINPAK in North America. More information about Winpak can be found below.
Wipak develops and manufactures highly innovative premium-quality flexible packaging solutions for Food products and Medical Instruments and Devices.
www.wipak.com
https://www.linkedin.com/company/wipak/
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units. The first unit covers the advisory business with a clear focus on five key areas to drive growth across all regions. The second unit provides IP-driven managed services beyond SaaS and offers business-critical services to its clients, supporting their business success. The third unit provides the software for successful digital transformation. It is also designed to explore innovative business models with clients and partners by driving the financing and development of start-ups and leveraging ecosystems.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
Twitter: @BearingPoint
View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005056/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release
- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release
New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release
Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release
Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
